Biotech · Private company
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Track this companyFree. Adds Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) to your Dealase workspace and tells you when its record changes.
Clinical trials42 recruiting or active
Pipeline programs13From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline13
- AtezolizumabPhase 2 · Small-Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- GocatamigPhase 2 · Small-Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- HPN424 1 Prime Step IV 225-300 ng/kg TargetPhase 2 · Advanced Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- HPN424 2 Prime Step IV 300 ng/kg TargetPhase 2 · Advanced Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- HPN424 2 Prime Step IV 450 ng/kg TargetPhase 2 · Advanced Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- HPN424 Fixed IV 1.3 to 150 ng/kgPhase 2 · Advanced Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- HPN424 Fixed SCPhase 2 · Advanced Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- HPN424 Prime Step IV 36 ng/kg TargetPhase 2 · Advanced Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- Ifinatamab Deruxtecan (I-DXd)Phase 2 · Small-Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- 2 Prime Step IV 900-14000 ng/kg TargetPhase 1 · Advanced Cancers Associated With Mesothelin ExpressionClinicalTrials.gov · fetched Nov 12, 2026
- HPN536 1 Prime Step IV 600-1200 ng/kg TargetPhase 1 · Advanced Cancers Associated With Mesothelin ExpressionClinicalTrials.gov · fetched Nov 12, 2026
- HPN536 Fixed IV 6 to 560 ng/kgPhase 1 · Advanced Cancers Associated With Mesothelin ExpressionClinicalTrials.gov · fetched Nov 12, 2026
- MK-4002Phase 1 · Multiple Myeloma in RelapseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Dec 14, 2020ClinicalTrials.gov NCT04471727 · fetched Nov 12, 2026
- Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)PHASE1 · ACTIVE_NOT_RECRUITING · started Apr 13, 2020ClinicalTrials.gov NCT04184050 · fetched Nov 12, 2026
- Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin ExpressionPHASE1 · COMPLETED · started Apr 16, 2019ClinicalTrials.gov NCT03872206 · fetched Nov 12, 2026
- Study of HPN424 in Patients With Advanced Prostate CancerPHASE1_PHASE2 · TERMINATED · started Jul 24, 2018ClinicalTrials.gov NCT03577028 · fetched Nov 12, 2026